Boston Scientific reported Q2 2024 net sales of $4.120 billion, up 14.5% year-over-year, with 16.1% operational growth. Adjusted EPS rose to $0.62 from $0.53 in Q2 2023. Growth was primarily driven by strong commercial execution across businesses, led by rapid adoption of the Farapulse Pulsed Field Ablation System following U.S. launch in early 2024.The Cardiology segment saw 20.1% growth, while MedSurg grew 9.0%. Emerging Markets net sales increased 14.8% on a reported basis. The company maintained its financial covenant of maximum leverage ratio at 3.75 times and had $2.913 billion in unrestricted cash as of June 30, 2024.Boston Scientific announced agreements to acquire Axonics for $3.670 billion and Silk Road Medical for $1.260 billion, expected to close in H2 2024. The company also completed a €2.000 billion senior notes offering in Q1 2024 to fund acquisitions and repay debt. Management remains focused on innovation, global expansion, and cost optimization to drive future growth.

Boston Scientific reported Q2 2024 net sales of $4.120 billion, up 14.5% year-over-year, with 16.1% operational growth. Adjusted EPS rose to $0.62 from $0.53 in Q2 2023. Growth was primarily driven by strong commercial execution across businesses, led by rapid adoption of the Farapulse Pulsed Field Ablation System following U.S. launch in early 2024.The Cardiology segment saw 20.1% growth, while MedSurg grew 9.0%. Emerging Markets net sales increased 14.8% on a reported basis. The company maintained its financial covenant of maximum leverage ratio at 3.75 times and had $2.913 billion in unrestricted cash as of June 30, 2024.Boston Scientific announced agreements to acquire Axonics for $3.670 billion and Silk Road Medical for $1.260 billion, expected to close in H2 2024. The company also completed a €2.000 billion senior notes offering in Q1 2024 to fund acquisitions and repay debt. Management remains focused on innovation, global expansion, and cost optimization to drive future growth.